When TIME magazine does a piece on your plight - it's definitely gaining public interest. The fact that 1 in 3 people affected by Type 1 diabetes manipulate their insulin to lose weight is an eye-opening statistic. This lethal coping mechanism is termed diabulemia and a major national TV show is seeking diabulmics for a "sensitive, accurate portrayal of the condition" - at least that is what they told me.

I volunteered myself for the interview. I've struggled with diabulemia for the past 15 years until I did something a doctor would NEVER recommend. I called the station back - it was CNN. I divulged what a day in the life was like when I practiced diabulemia -- and I was good at it! When I told the interviewer that I noticed a world of difference when I changed my insulin from human synthetic to natural animal, she was surprised (so was my doctor). The key to mitigating my angst with insulin was getting the message to my brain at the same time the rest of my body was getting the glucose. This is less effective in newer insulin analogues. Big Pharma does not profit by selling natural vertebrate insulin even if it is better for hormonal response in suppressing appetite and preventing your body from entering ketoacidosis (DKA). Big Pharma profits if they own the patent for the specific insulin analogue you use. In my land of milk and honey - I realized Big Pharma is not my mom, not my dad and not my best friend. Big Pharma is not personal -- Big Pharma is business. So I took my business elsewhere because I didn't like the way Big Pharma was handling my business.

I don't mind explaining my abusive relationship with insulin if it helps anybody struggling with diabulemia. It's a shameful thing but it doesn't have to be. It's controversial but it's all true. For those of you considering your 15 minutes for diabulemia -- don't be concerned about your privacy. The TV show is planning to shoot the interview in shadow. If you wish to learn more about contributing to this documentary, please see The Sugar Shock.

Mad Money is a stock show on CNBC hosted by Jim Cramer - a well-known iron fist on Wall Street. He has a following of stock enthusiasts who regard his recommendations (buy or sell) as gospel. Why is he so good at what he does? He just wants to help you make money.

And to this end -- the reason I bring Cramer's passionate drive to The Diabetes Blog is simple: last week he called Novo Nordisk as a SELL. Cramer said he's beginning to worry about a backlash on drug stocks. He advised that viewers should not be greedy and should take gains in Novo Nordisk (NVO).

Perhaps the NY Times article raised some eyebrows at Big Pharma. It appears doctors are receiving handsome gifts and stipends for handing out samples of drugs that were not all that safe for most patients. The payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes. In light of this blood curdling synopsis Novo got a dishonorable mention. Novo Nordisk professes to operate their company in two parts: biopharmaceuticals and Diabetes Care. The Diabetes Care segment provides insulin analogues, human insulin and insulin-related products, and oral antidiabetic drugs.

The cross examination of the C-peptide disappearing act and mysterious insulin auto-antibodies appearing where they shouldn't is just getting started. Thanks for making them sweat, Cramer!

In the next 3 to 5 years, we will have a new generation of control upon us providing continuous glucose monitoring. Some of these marvelous technologies will not require a drop of blood, while others will embody the tried-and-true stick-to-itiveness we all know and loathe.

Please join me as we browse the isles of things to come (and things now available) for continuous glucose monitoring.

The DexCom STS Continuous Glucose Monitoring System is a glucose sensor that reports glucose values every 5 minutes for up to 72 hours. The sensor is inserted in the abdomen. After a 2 hour start-up period, the STS System is calibrated with 2 fingerstick measurements taken by a traditional glucose meter. Checkout Amy Tenderich's review on Diabetes Mine of the DexCom Continuous Glucose Monitoring Sytem.

MiniMed Medtronic has 3 different versions: the Gold, the Guardian RT, and the Paradigm Real-Time Continuous Monitor.

Menarini GlucoDay S is a device worn by the patient for the continuous monitoring of glucose in the subcutaneous interstitial fluid. Monitoring is performed via insertion in the abdominal region of a microfibre for dialysis having the diameter of a human hair. Inside the microfibre a solution transports the patient's glucose to a biosensor within the instrument.

M-Biotech Glucose Biosensor is a minimally invasive implantation for painless and convenient monitoring. The key feature of our efficient Glucose Biosensor is the combination of a glucose-sensitive hydrogel and a miniature pressure sensor. Glucose-responsive hydrogels are biocompatible materials that either swell or contract when the glucose concentrations change in the body fluid surrounding the hydrogel.

The PreciSense System includes a microcapsule placement unit and a light detecting non-invasive reader unit. The microcapsule placement unit poses the right dose of glucose-responding microcapsules in the upper layer of the skin, painlessly. The glucose assay components in the microcapsules generate a fluorescence signal that corresponds to the glucose level. The non-invasive reader unit monitors this glucose binding event through FRET, Fluorescence Resonance Energy Transfer, which is directly related to the concentration of glucose.

Sensors for Medicine and Science glucose sensor is implanted under the skin in a short outpatient procedure. The sensor automatically measures interstitial glucose every few minutes, without any user intervention. The sensor implant will communicate wirelessly with a small external reader.

Synthetic Blood Implanted Glucose Biosensor claims to offer significantly more accurate glucose readings in a range of 30-500 mg/dl. The implanted Glucose Biosensor continuously monitors blood glucose without the need for finger sticks. The most accurate glucose monitor available, the implanted biosensor can be programmed to monitor blood glucose according to a predetermined schedule, thus eliminating problems of patient compliance. The sensor alarms for dangerous, life threatening conditions such as hypoglycemia.

GlucoLight Corporation is developing a low-cost non-invasive blood glucose monitor for home use by diabetic patents. GlucoLight's unique optical approach, microScatterTM (microscatter) technology, is based on patented technologies in the area of Optical Coherence Tomography (OCT) and Low Coherence Interferometry (LCI). There is a working prototype with published clinical data on healthy volunteers.

The GlucoWatch G2 Biographer was approved to detect glucose level trends and track patterns in people with diabetes. It must be used along with conventional blood glucose monitoring of blood samples. The device, which looks like a wristwatch, pulls body fluid from the skin using small electric currents. It can provide six measurements per hour for 13 hours. (See David Mendosa's review).

The Motley Fool investment advice team is running a little opinion piece on MSNBC. The topic? Exubera, Pfizer's inhalable insulin product, which is all set to enter the US pharmaceuticals market this summer. Like many market analysts, the author Stephen D. Simpson is intrigued by all the fuss and hype surrounding the drug.

The thing that strikes me as funny, the more I read about Exubera, is that the drug seems to be a popular topic of discussion for people interested in finance and investment. That is, they are tracking this drug more avidly than are people likely to be prescribing or taking it!

The reason, of course, is money. Will it or won't it be the moneymaker it's projected to be? Interestingly, Simpson's not sure. He says he's never seen as much uncertainty about a drug -- that some predict it will be a goldmine for investors and a diabetes care revolution, while others say it is so overpriced that most diabetics will stick with shots, thanks very much. Simpson's final word: money will be made, even if the market response is officially lower than estimated.

Adding to the chorus of reasons to cut saturated fat from the diet is the fact that it appears to negatively affect insulin function. For that reason, the more saturated fats you consume, the greater your risk of developing diabetes. That is, in addition to all the other scary stuff that saturated fats can do to your health -- in particular, raising your cholesterol levels and increasing your risk of cancer and heart disease. It works like this: saturated fat decreases the ability of the pancreas to secrete insulin. Obviously, this puts you at risk for developing diabetes.

However, in addition, insulin-related problems are also associated with a host of other health problems. Karen Collins, writing for MSNBC, talks in her latest column about polycystic ovarian syndrome as one example of a health disorder that has been linked to poor pancreas function. She suggests people cut saturated fat from the diet by, for example, cooking with olive oil instead of butter. It seems to me, though, that the reasons many Americans get too much saturated fat in the diet is not through their own cooking, but through the consumption of processed foods (see delicious-looking example in picture), whether from the grocery store or a restaurant. What do you think?